187 related articles for article (PubMed ID: 15019535)
1. Peroxynitrite-mediated oxidative modification of low-density lipoprotein by aqueous extracts of cigarette smoke and the preventive effect of fluvastatin.
Yamaguchi Y; Matsuno S; Kagota S; Haginaka J; Kunitomo M
Atherosclerosis; 2004 Feb; 172(2):259-65. PubMed ID: 15019535
[TBL] [Abstract][Full Text] [Related]
2. Fluvastatin reduces modification of low-density lipoprotein in hyperlipidemic rabbit loaded with oxidative stress.
Yamaguchi Y; Matsuno S; Kagota S; Haginaka J; Kunitomo M
Eur J Pharmacol; 2002 Feb; 436(1-2):97-105. PubMed ID: 11834252
[TBL] [Abstract][Full Text] [Related]
3. Protective effect of fluvastatin sodium (XU-62-320), a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, on oxidative modification of human low-density lipoprotein in vitro.
Suzumura K; Yasuhara M; Tanaka K; Suzuki T
Biochem Pharmacol; 1999 Mar; 57(6):697-703. PubMed ID: 10037456
[TBL] [Abstract][Full Text] [Related]
4. Facilitated nitration and oxidation of LDL in cigarette smokers.
Yamaguchi Y; Haginaka J; Morimoto S; Fujioka Y; Kunitomo M
Eur J Clin Invest; 2005 Mar; 35(3):186-93. PubMed ID: 15733073
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effects of fluvastatin and its metabolites on hydrogen peroxide-induced oxidative destruction of hemin and low-density lipoprotein.
Suzumura K; Tanaka K; Yasuhara M; Narita H
Biol Pharm Bull; 2000 Jul; 23(7):873-8. PubMed ID: 10919369
[TBL] [Abstract][Full Text] [Related]
6. Antioxidants suppress plasma levels of lectinlike oxidized low-density lipoprotein receptor-ligands and reduce atherosclerosis in watanabe heritable hyperlipidemic rabbits.
Oka K; Yasuhara M; Suzumura K; Tanaka K; Sawamura T
J Cardiovasc Pharmacol; 2006 Oct; 48(4):177-83. PubMed ID: 17086097
[TBL] [Abstract][Full Text] [Related]
7. Participation of peroxynitrite in oxidative modification of LDL by aqueous extracts of cigarette smoke.
Yamaguchi Y; Kagota S; Haginaka J; Kunitomo M
FEBS Lett; 2002 Feb; 512(1-3):218-22. PubMed ID: 11852083
[TBL] [Abstract][Full Text] [Related]
8. Fluvastatin, an HMG-CoA reductase inhibitor, protects LDL from oxidative modification in hypercholesterolemic rabbits.
Yasuhara M; Suzumura K; Tanaka K; Takahashi M; Aoki S; Odawara A; Narita H; Suzuki T
Biol Pharm Bull; 2000 May; 23(5):570-4. PubMed ID: 10823666
[TBL] [Abstract][Full Text] [Related]
9. Oxidants in cigarette smoke extract modify low-density lipoprotein in the plasma and facilitate atherogenesis in the aorta of Watanabe heritable hyperlipidemic rabbits.
Yamaguchi Y; Matsuno S; Kagota S; Haginaka J; Kunitomo M
Atherosclerosis; 2001 May; 156(1):109-17. PubMed ID: 11369003
[TBL] [Abstract][Full Text] [Related]
10. Effect of fluvastatin sodium on the smooth muscle cells in atherosclerotic plaques. In vivo study using low-density lipoprotein receptor deficient Watanabe heritable hyperlipidemic (WHHL) rabbits.
Shiomi M; Ito T; Tsukada T; Shiraishi M; Yata T
Arzneimittelforschung; 1998 Jun; 48(6):680-5. PubMed ID: 9689427
[TBL] [Abstract][Full Text] [Related]
11. High dose of fluvastatin sodium (XU62-320), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, lowers plasma cholesterol levels in homozygous Watanabe-heritable hyperlipidemic rabbits.
Kurokawa J; Hayashi K; Toyota Y; Shingu T; Shiomi M; Kajiyama G
Biochim Biophys Acta; 1995 Oct; 1259(1):99-104. PubMed ID: 7492622
[TBL] [Abstract][Full Text] [Related]
12. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits.
Rikitake Y; Kawashima S; Takeshita S; Yamashita T; Azumi H; Yasuhara M; Nishi H; Inoue N; Yokoyama M
Atherosclerosis; 2001 Jan; 154(1):87-96. PubMed ID: 11137086
[TBL] [Abstract][Full Text] [Related]
13. Valsartan therapy has additive anti-oxidative effect to that of fluvastatin therapy against low-density lipoprotein oxidation: studies in hypercholesterolemic and hypertensive patients.
Hussein O; Shneider J; Rosenblat M; Aviram M
J Cardiovasc Pharmacol; 2002 Jul; 40(1):28-34. PubMed ID: 12072574
[TBL] [Abstract][Full Text] [Related]
14. Effects of fluvastatin therapy on lipids, antioxidants, oxidation of low density lipoproteins and trace metals.
Leonhardt W; Kurktschiev T; Meissner D; Lattke P; Abletshauser C; Weidinger G; Jaross W; Hanefeld M
Eur J Clin Pharmacol; 1997; 53(1):65-9. PubMed ID: 9349932
[TBL] [Abstract][Full Text] [Related]
15. Fluvastatin prevents renal injury and expression of lactin-like oxidized low-density lipoprotein receptor-1 in rabbits with hypercholesterolemia.
Yu YH; Wang Y; Dong B; Sun SZ; Chen Y; Meng XH; Liu ZZ
Chin Med J (Engl); 2005 Apr; 118(8):621-6. PubMed ID: 15899115
[TBL] [Abstract][Full Text] [Related]
16. Triglyceride metabolism in heterozygote of Watanabe heritable hyperlipidemic rabbit.
Naka Y; Yoshino G; Hirano T; Murata Y; Maeda E; Kazumi T; Kasuga M
Atherosclerosis; 1998 Feb; 136(2):325-32. PubMed ID: 9543104
[TBL] [Abstract][Full Text] [Related]
17. In vitro inhibitory effects of the optical isomers and metabolites of fluvastatin on copper ion-induced LDL oxidation.
Suzumura K; Odawara A; Yasuhara M; Tanaka K; Narita H; Suzuki T
Biol Pharm Bull; 1999 Sep; 22(9):971-4. PubMed ID: 10513623
[TBL] [Abstract][Full Text] [Related]
18. Effect of fluvastatin sodium on secretion of very low density lipoprotein and serum cholesterol levels. In vivo study using low density lipoprotein receptor deficient watanabe heritable hyperlipidemic rabbits.
Shiomi M; Shiraishi M; Yata T; Ito T
Arzneimittelforschung; 1994 Oct; 44(10):1154-6. PubMed ID: 7818592
[TBL] [Abstract][Full Text] [Related]
19. Functional evidence for anti-oxidant action of fluvastatin on low-density lipoprotein using isolated macrophages and aorta.
Kagota S; Yamaguchi Y; Nakamura K; Kunitomo M
Clin Exp Pharmacol Physiol; 2000; 27(5-6):401-5. PubMed ID: 10831243
[TBL] [Abstract][Full Text] [Related]
20. S 12340: a potent inhibitor of the oxidative modification of low-density lipoprotein in vitro and ex vivo in WHHL rabbits.
Breugnot C; Privat S; Guillonneau C; Regnier G; Bouzom F; Vilaine JP; Lenaers A
J Pharmacol Exp Ther; 1994 May; 269(2):515-20. PubMed ID: 8182520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
